Blood Res.  2015 Sep;50(3):181-182. 10.5045/br.2015.50.3.181.

Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia

• Niscola P
• Tendas A
• Merola R
• Orlandi G
• Scaramucci L
• de Fabritiis P

• KMID: 2172763
• DOI: http://doi.org/10.5045/br.2015.50.3.181

Abstract

No abstract available.

MeSH Terms

Anemia, Refractory*
Azacitidine*
Erythropoietin*
Leukemia, Myelomonocytic, Chronic*
Azacitidine
Erythropoietin

Reference

1. Niscola P, Tendas A, Scaramucci L, Giovannini M, Fratoni S, de Fabritiis P. Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. Blood Res. 2013; 48:152–153. PMID: 23826588.

2. Tendas A, Cupelli L, Siniscalchi A, et al. Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. Mediterr J Hematol Infect Dis. 2014; 6:e2014020. PMID: 24678397.

3. Tobiasson M, Dybedahl I, Holm MS, et al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood Cancer J. 2014; 4:e189. PMID: 24608733.

4. Efficace F, Gaidano G, Breccia M, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol. 2015; 168:361–370. PMID: 25272332.

5. Spiriti MA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005; 84:167–176. PMID: 15592833.

6. Niscola P, Tendas A, Giovannini M, et al. Transfusions at home in patients with myelodysplastic syndromes. Leuk Res. 2012; 36:684–688. PMID: 22336393.

7. Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 2010; 34:1576–1588. PMID: 20149927.

8. Breccia M, Voso MT, Maurillo L, et al. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. Am J Hematol. 2014; 89:565. PMID: 24458879.

9. Itzykson R, Thépot S, Beyne-Rauzy O, et al. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk Res. 2012; 36:397–400. PMID: 22177456.

10. Breccia M, Loglisci G, Salaroli A, et al. Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies. Leuk Res. 2012; 36:682–683. PMID: 22424713.